Taking people in CzechiaPhase 3
Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
Key facts
- Who runs it
- Incyte Corporation
- Where
- Ostrava, Prague, and Prague 10, CzechiaSee the 5 sitesAlso in 20 other countries, 296 sites
- Trial code
- Status
- Recruiting
- Phase
- Phase 3
- People taking part
- 600 people, planned
- Started
- 28 Feb 2025
- Expected to end
- 28 Feb 2028
- Type of study
- Interventional
- Treatments tested
- povorcitinib
- Record updated
- 30 October 2026
Who can take part
- Age
- 18 years and older
- Sex
- Women and men
- Healthy volunteers
- Cannot take part
The registry criteria, word for word
Show all 14 criteriaShow less
Who can take part
- Ability to comprehend and willingness to sign a written ICF for the study
- Completed the treatment period of a predetermined, Incyte-sponsored, povorcitinib parent study without safety or tolerability concerns, per investigator's assessment
- Received clinical benefit from treatment with study drug during the parent study, as determined by the investigator
- Demonstrated compliance, as assessed by the investigator, with the parent Protocol requirements
- Willingness to avoid pregnancy or fathering children as defined in the protocol
- Willingness and ability to comply with the study Protocol and procedures
Who cannot take part
- Had temporary study drug interruption due to safety and/or efficacy reasons at or after the final visit of the parent study
- Received at least 1 dose of either of the following therapies within the 28 days prior to starting treatment in this rollover study:; Biologic immunomodulator (examples include but are not limited to adalimumab, bimekizumab, dupilumab, infliximab, nemolizumab, secukinumab); Live, attenuated vaccine
- Plans for administration of a live, attenuated vaccine during this study or within 8 weeks after the last dose of study drug
- Currently enrolled in any other clinical study involving an investigational product or any other type of medical research judged not to be scientifically or medically compatible with this study
- Known hypersensitivity or severe reaction to povorcitinib or excipients of povorcitinib and/or other products in the same class
- Any condition that would, in the investigator's and/or sponsor's judgment, interfere with full participation in the study, including administration of study drug and attending required study visits; pose a significant risk to the participant; or interfere with interpretation of study data; Other protocol-defined Inclusion/Exclusion Criteria may apply
- Had been permanently discontinued from study treatment during the parent study
- Women who are pregnant (or who are considering pregnancy) or breastfeeding
Where in Czechia
Also in 20 other countries, 296 sites
- Fakultni nemocnice OstravaOstrava, CzechiaTaking people
- Fakultni nemocnice v MotolePrague, CzechiaTaking people
- Sanatorium Profesora ArenbergeraPrague, CzechiaTaking people
- Sanixtra CZ s.r.o.Prague, CzechiaTaking people
- Clintrial s.r.o.Prague 10, CzechiaTaking people
About the trial
What the trial wants to find out
Rollover study for participants from predetermined, Incyte-sponsored parent clinical trials of povorcitinib.
The group in the trial
- povorcitinibTreatment being tested
Participants will receive povorcitinib treatment with the same schedule and dose options as the study in which they originally enrolled.
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov and on the EU's official list of trials (CTIS).
- Official title
- A Phase 3b, Multicenter, Rollover Study for Participants Previously Enrolled in Clinical Trials of Povorcitinib
- Record updated
- 30 October 2026